Carnegie acted as bookrunner in the directed new share issue of 1,370,000 shares at a subscription price of SEK 67 per share. Xspray is a product development company with several product candidates in clinical development. Xspray employs a patent protected technology platform to develop improved and generic versions of already marketed drugs, primarily protein kinase inhibitors (PKIs) for cancer treatment. December 2018.
Healthcare
Directed new share issue in Xspray Pharma AB (SE) — SEK 92 million
December 2018